Form D · Biotechnology

MBF Therapeutics, Inc.

Ambler, PA · CIK 0001458729

Offering snapshot reported Jan 8, 2024 · SEC filing

Reported sold
$105K
Offering amount: $500K
Investors reported
6
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 29, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 8, 2024Initial$105,000No comparison6SEC filing
Sep 1, 2020Initial$604,292No comparison16SEC filing
May 24, 2019Amendment$605,000$180,000vs May 2, 201816SEC filing
May 2, 2018Amendment$425,000$295,000vs Nov 16, 201710SEC filing
Nov 16, 2017Initial$130,000No comparison2SEC filing
Nov 21, 2016Initial$1,095,185No comparison14SEC filing
Mar 15, 2010Amendment$345,000$245,000vs Mar 17, 20097SEC filing
Mar 17, 2009Initial$100,000No comparisonNot reportedSEC filing

Offering details

Securities
Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-501849

Source: Form D, filed Jan 8, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Chris Bunge Director
Christopher Cashman Director
Joseph Connor Director
Lorraine Keller Executive
Aris Persidis Director
Christopher Ragland Director
Dhiren Thakker Director
Thomas Tillett Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
640 Woodbrook Drive
Ambler, PA, 19002